5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair

Oncotarget

Volumn 6, Issue 14, 2015, Pages 12574-12586

  Srinivas, Upadhyayula Sai ^a   Dyczkowski, Jerzy ^a   Beißbarth, Tim ^a   Gaedcke, Jochen ^a   Mansour, Wael Y ^b,c   Borgmann, Kerstin ^b   Dobbelstein, Matthias ^a  

^a UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

^b UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^c CAIRO UNIVERSITY   (Egypt)

Author keywords

5 fluorouracil; Colorectal cancer; Homologous recombination repair; Rad51; Radiochemotherapy

Indexed keywords

BRCA2 PROTEIN; DOUBLE STRANDED DNA; FLUOROURACIL; HISTONE H2AX; RAD51 PROTEIN; ZINOSTATIN; ANTINEOPLASTIC AGENT;

ARTICLE; CELL PROLIFERATION; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; DNA SYNTHESIS; DOUBLE STRANDED DNA BREAK; DRUG EFFICACY; HUMAN; HUMAN CELL; HUMAN TISSUE; PROTEIN TARGETING; RECOMBINATION REPAIR; UPREGULATION; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; CONFOCAL MICROSCOPY; DNA MICROARRAY; DRUG EFFECTS; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENETICS; IMMUNOBLOTTING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CHEMORADIOTHERAPY; COLORECTAL NEOPLASMS; DNA BREAKS, DOUBLE-STRANDED; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; IMMUNOBLOTTING; MICROSCOPY, CONFOCAL; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; RECOMBINATIONAL DNA REPAIR; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 84930022939     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.3728     Document Type: Article

References (37)

1. Shike M, Winawer SJ, Greenwald PH, Bloch A, Hill MJ and Swaroop SV. Primary prevention of colorectal cancer. The WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ. 1990; 68:377-385.
2. Haggar FA and Boushey RP. Colorectal cancer epidemiology: incidence, mortality, survival, and risk factors. Clin Colon Rectal Surg. 2009; 22:191-197.
3. Longley DB, Harkin DP and Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer. 2003; 3:330-338.
4. Mazouzi A, Velimezi G and Loizou JI. DNA replication stress: causes, resolution and disease. Exp Cell Res. 2014; 329:85-93.
5. Dobbelstein M and Sorensen CS. Exploiting replicative stress to treat cancer. Nat Rev Drug Discov. in press.
6. Di Micco R, Fumagalli M, Cicalese A, Piccinin S, Gasparini P, Luise C, Schurra C, Garre M, Nuciforo PG, Bensimon A, Maestro R, Pelicci PG and d'Adda di Fagagna F. Oncogeneinduced senescence is a DNA damage response triggered by DNA hyper-replication. Nature. 2006; 44:638-642.
7. Bartkova J, Horejsi Z, Koed K, Kramer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Orntoft T, Lukas J and Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434:864-870.
8. Sampath D, Rao VA and Plunkett W. Mechanisms of apoptosis induction by nucleoside analogs. Oncogene. 2003; 22:9063-9074.
9. Martino-Echarri E, Henderson BR and Brocardo MG. Targeting the DNA replication checkpoint by pharmacologic inhibition of Chk1 kinase: a strategy to sensitize APC mutant colon cancer cells to 5-fluorouracil chemotherapy. Oncotarget. 2014; 5:9889-9900.
10. Dobbelstein M and Moll U. Targeting tumour-supportive cellular machineries in anticancer drug development. Nat Rev Drug Discov. 2014; 13:179-196.
11. Hills SA and Diffley JF. DNA replication and oncogeneinduced replicative stress. Curr Biol. 2014; 24:R435-444.
12. Cimprich KA and Cortez D. ATR: an essential regulator of genome integrity. Nat Rev Mol Cell Biol. 2008; 9:616-627.
13. Matsuoka S, Ballif BA, Smogorzewska A, McDonald ER, 3rd, Hurov KE, Luo J, Bakalarski CE, Zhao Z, Solimini N, Lerenthal Y, Shiloh Y, Gygi SP and Elledge SJ. ATM and ATR substrate analysis reveals extensive protein networks responsive to DNA damage. Science. 2007; 316:1160-1166.
14. Rogakou EP, Pilch DR, Orr AH, Ivanova VS and Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem. 1998; 273:5858-5868.
15. Adamsen BL, Kravik KL and De Angelis PM. DNA damage signaling in response to 5-fluorouracil in three colorectal cancer cell lines with different mismatch repair and TP53 status. Int J Oncol. 2011; 39:673-682.
16. Falck J, Coates J and Jackson SP. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature. 2005; 434:605-611.
17. Bunting SF, Callen E, Kozak ML, Kim JM, Wong N, Lopez-Contreras AJ, Ludwig T, Baer R, Faryabi RB, Malhowski A, Chen HT, Fernandez-Capetillo O, D'Andrea A and Nussenzweig A. BRCA1 functions independently of homologous recombination in DNA interstrand crosslink repair. Mol Cell. 2012; 46:125-135.
18. Bunting SF, Callen E, Wong N, Chen HT, Polato F, Gunn A, Bothmer A, Feldhahn N, Fernandez-Capetillo O, Cao L, Xu X, Deng CX, Finkel T, Nussenzweig M, Stark JM and Nussenzweig A. 53BP1 inhibits homologous recombination in Brca1-deficient cells by blocking resection of DNA breaks. Cell. 2010; 141:243-254.
19. Maacke H, Jost K, Opitz S, Miska S, Yuan Y, Hasselbach L, Luttges J, Kalthoff H and Sturzbecher HW. DNA repair and recombination factor Rad51 is over-expressed in human pancreatic adenocarcinoma. Oncogene. 2000; 19:2791-2795.
20. Maacke H, Opitz S, Jost K, Hamdorf W, Henning W, Kruger S, Feller AC, Lopens A, Diedrich K, Schwinger E and Sturzbecher HW. Over-expression of wild-type Rad51 correlates with histological grading of invasive ductal breast cancer. Int J Cancer. 2000; 88:907-913.
21. Kauffmann A, Rosselli F, Lazar V, Winnepenninckx V, Mansuet-Lupo A, Dessen P, van den Oord JJ, Spatz A and Sarasin A. High expression of DNA repair pathways is associated with metastasis in melanoma patients. Oncogene. 2008; 27:565-573.
22. Winnepenninckx V, Lazar V, Michiels S, Dessen P, Stas M, Alonso SR, Avril MF, Ortiz Romero PL, Robert T, Balacescu O, Eggermont AM, Lenoir G, Sarasin A, Tursz T, van den Oord JJ and Spatz A. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst. 2006; 98:472-482.
23. Sarasin A and Kauffmann A. Overexpression of DNA repair genes is associated with metastasis: a new hypothesis. Mutat Res. 2008; 659:49-55.
24. Pierce AJ, Johnson RD, Thompson LH and Jasin M. XRCC3 promotes homology-directed repair of DNA damage in mammalian cells. Genes Dev. 1999; 13:2633-2638.
25. Fattah F, Lee EH, Weisensel N, Wang Y, Lichter N and Hendrickson EA. Ku regulates the non-homologous end joining pathway choice of DNA double-strand break repair in human somatic cells. PLoS Genet. 2010; 6(2):e1000855.
26. Wohlbold L and Fisher RP. Behind the wheel and under the hood: functions of cyclin-dependent kinases in response to DNA damage. DNA repair. 2009; 8:1018-1024.
27. Huang F, Motlekar NA, Burgwin CM, Napper AD, Diamond SL and Mazin AV. Identification of specific inhibitors of human RAD51 recombinase using highthroughput screening. ACS Chem Biol. 2011; 6:628-635.
28. Violette S, Poulain L, Dussaulx E, Pepin D, Faussat A-MM, Chambaz J, Lacorte J-MM, Staedel C and Lesuffleur T. Resistance of colon cancer cells to long-term 5-fluorouracil exposure is correlated to the relative level of Bcl-2 and Bcl-X(L) in addition to Bax and p53 status. Int J Cancer. 2002; 98:498-504.
29. Meyers M, Wagner MW, Hwang HS, Kinsella TJ and Boothman DA. Role of the hMLH1 DNA mismatch repair protein in fluoropyrimidine-mediated cell death and cell cycle responses. Cancer Res. 2001; 61:5193-5201.
30. Morgan MA, Parsels LA, Zhao L, Parsels JD, Davis MA, Hassan MC, Arumugarajah S, Hylander-Gans L, Morosini D, Simeone DM, Canman CE, Normolle DP, Zabludoff SD, Maybaum J and Lawrence TS. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair. Cancer Res. 2010; 70:4972-4981.
31. Sorensen CS, Hansen LT, Dziegielewski J, Syljuasen RG, Lundin C, Bartek J and Helleday T. The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair. Nat Cell Biol. 2005; 7:195-201.
32. Helleday T, Petermann E, Lundin C, Hodgson B and Sharma RA. DNA repair pathways as targets for cancer therapy. Nat Rev Cancer. 2008; 8:193-204.
33. Wyatt MD and Wilson DM. Participation of DNA repair in the response to 5-fluorouracil. Cell Mol Life Sci. 2009; 66:788-799.
34. Bartkova J, Horejsí Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J and Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature. 2005; 434:864-870.
35. Connell PP, Jayathilaka K, Haraf DJ, Weichselbaum RR, Vokes EE and Lingen MW. Pilot study examining tumor expression of RAD51 and clinical outcomes in human head cancers. Int J Oncol. 2006; 28:1113-1119.
36. Tennstedt P, Fresow R, Simon R, Marx A, Terracciano L, Petersen C, Sauter G, Dikomey E and Borgmann K. RAD51 overexpression is a negative prognostic marker for colorectal adenocarcinoma. Int J Cancer. 2013; 132:2118-2126.
37. Nakanoko T, Saeki H, Morita M, Nakashima Y, Ando K, Oki E, Ohga T, Kakeji Y, Toh Y and Maehara Y. Rad51 expression is a useful predictive factor for the efficacy of neoadjuvant chemoradiotherapy in squamous cell carcinoma of the esophagus. Ann Surg Oncol. 2014; 21:597-604.